Every 10-Q that Astrana Health Inc. (ASTH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ASTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASTH filings page.
Astrana Health, Inc. reported substantial growth for the quarter and six months ended June 30, 2026. Quarterly capitation and other revenue rose to $972.5 million, with net income attributable to Astrana increasing to $19.7 million, or $0.40 basic and diluted EPS. For the first half of 2026, revenue reached $1.94 billion and net income attributable to Astrana was $34.2 million with diluted EPS of $0.69.
Total assets were $2.28 billion and total liabilities $1.68 billion, with stockholders’ equity at $830.2 million. Cash and cash equivalents stood at $400.8 million and total debt at $948.3 million, while operating activities generated $100.8 million of cash in the first half. Medical liabilities increased to $415.8 million, reflecting higher medical costs alongside growth in the business.
Astrana Health, Inc. reported strong growth for the quarter ended March 31, 2026, driven by its value-based care model and the 2025 Prospect acquisition. Total revenue rose to $965.1 million, up from $620.4 million a year earlier, with capitation revenue reaching $892.9 million.
Net income attributable to Astrana increased to $14.4 million from $6.7 million, and diluted earnings per share improved to $0.29 from $0.14. Operating income was $28.5 million as higher medical and administrative costs followed the larger network.
Astrana ended the quarter with $478.4 million in cash and cash equivalents and total assets of $2.36 billion, including $874.8 million of goodwill from acquisitions. Long-term debt stood at $1.04 billion, largely from financing the Prospect deal, and medical liabilities were $439.3 million, reflecting obligations under its risk-bearing contracts.
Astrana Health (ASTH) reported Q3 2025 results and closed a large acquisition. Revenue for the quarter was $956.0 million, up from $478.7 million a year ago, driven by higher capitation revenue. Income from operations was $19.2 million versus $28.4 million last year. Net income attributable to Astrana was $0.4 million with diluted EPS of $0.01, compared to $16.1 million and $0.33 a year earlier.
For the nine months, revenue was $2.23 billion versus $1.37 billion, while net income attributable to Astrana was $16.5 million (diluted EPS $0.33) versus $50.1 million (diluted EPS $1.04) last year.
On July 1, 2025, Astrana acquired Prospect for $674.9 million, financed by a $707.3 million five‑year delayed draw term loan, significantly expanding its provider network. Goodwill rose to $863.3 million and intangible assets to $285.1 million at quarter‑end. Cash and cash equivalents increased to $462.2 million, and total debt (current and long‑term) was $1.05 billion. Operating cash flow for the nine months was $117.5 million. As of November 7, 2025, there were 56,288,415 common shares outstanding, including 6,132,802 treasury shares held by APC.